TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics
03 nov. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region...
TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program
01 nov. 2022 16h07 HE
|
TFF Pharmaceuticals, Inc.
Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated...
TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs
01 nov. 2022 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
11 oct. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
26 sept. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting
22 sept. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation
08 sept. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient Patient...
TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
11 août 2022 16h05 HE
|
TFF Pharmaceuticals, Inc.
Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms...
TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022
02 août 2022 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...